The study of the crystal structure of proplasmepsin IV from P. falciparum and its comparison with the structures of the mature enzyme and of other proplasmepsins show the flexibility that characterizes the aspartic protease zymogens from malaria parasites.
Keywords: malaria, proplasmepsin IV, Plasmodium falciparum, aspartic protease zymogen
Abstract
Plasmepsin IV from Plasmodium falciparum (PM IV) is a promising target for the development of novel antimalarial drugs. Here, the crystal structure of the truncated zymogen of PM IV (pPM IV), consisting of the mature enzyme plus a prosegment of 47 residues, has been determined at 1.5 Å resolution. pPM IV presents the fold previously described for studied proplasmepsins, displaying closer similarities to proplasmepin IV from P. vivax (pPvPM) than to the other two proplasmepsins from P. falciparum. The study and comparison of the pPM IV structure with the proplasmepsin structures described previously provide information about the similarities and differences in the inactivation–activation mechanisms among the plasmepsin zymogens.
1. Introduction
The malaria parasite continues to be one of the leading causes of death in many developing countries (World Health Organization, 2013 ▸). With the development of resistance against currently available treatments, the discovery of new therapeutics is imperative. There are four species of malaria parasite that infect humans: Plasmodium falciparum (Pf), P. malariae (Pm), P. ovale (Po) and P. vivax (Pv). Pf is responsible for the majority of deaths associated with malarial infections, while Pm, Po and Pv are associated with chronic infections, in some cases for an individual’s entire life.
During the asexual stage of the parasite life cycle, it invades red blood cells and degrades haemoglobin. This is performed by plasmodial aspartic proteases, plasmepsins, in a specialized compartment called the food vacuole. It has long been known that treating the parasites in culture with aspartic protease inhibitors kills them (Francis et al., 1994 ▸). This fact, along with their key function in haemoglobin degradation, makes the plasmepsin enzymes viable drug targets (Coombs et al., 2001 ▸). P. falciparum contains four plasmepsin enzymes in the food vacuole: PM I, PM II, histoaspartic protease (HAP) and PM IV. In vitro studies have shown that PM IV is capable of digesting haemoglobin, but is more active against denatured globin (Banerjee et al., 2002 ▸). Another function that has been attributed to PM II and PM IV is the degradation of spectrin and other components of the erythrocyte cytoskeleton (Le Bonniec et al., 1999 ▸; Wyatt & Berry, 2002 ▸). PM IV is the orthologue of the unique plasmepsin present in the food vacuole of the other three species infecting man (PmPM, PvPM and PoPM; Dame et al., 2003 ▸). The sequence similarity among the different species is between 70 and 87% (Bernstein et al., 2003 ▸). Therefore, there is a growing interest in the structural characterization of this class of enzymes to aid structure-based drug design (Jaudzems et al., 2014 ▸; Recacha et al., 2015 ▸; Rasina et al., 2016 ▸).
Plasmepsins, like many other proteases, are synthesized as zymogens, inactive precursors of the enzymes which provide protection from proteolysis, stabilize the inactive form and prevent the entry of the substrate into the active site. In vivo, a maturase converts Pf proplasmepsins (pPMs) to the active proteinases, but recombinant pPM II and pPM IV can also be activated autocatalytically in vitro at acidic pH (Hill et al., 1994 ▸).
The Protein Data Bank contains four crystal structures of three proplasmepsins: pPvPM from P. vivax (PDB entry 1miq; Bernstein et al., 2003 ▸) and pPM II [PDB entries 1pfz (Bernstein et al., 1999 ▸) and 5bwy (R. Recacha, I. Akopjana, K. Tars & K. Jaudzems, unpublished work)] and pHAP (PDB entry 3qvc; Bhaumik et al., 2011 ▸) from P. falciparum. All of these proenzymes are folded into three topologically similar domains (Fig. 1 ▸ a): the N- and C-terminal domains are anchored to the central motif, a six-stranded antiparallel β-sheet.
Figure 1.
Structural view of the conversion of pPM IV (a) to PM IV (b). The regions discussed in the main text are labelled. The prosegment is shown in blue, the N-terminal 13 amino acids of the mature sequence in red, the flap loop in yellow and the catalytic Asp34–Asp214 dyad as sticks.
In this paper, we present the crystal structure of pPM IV and compare it with the structures of the mature enzyme and the proplasmepsins pPvPM, pPM II and pHAP. pPM IV has a higher sequence homology (Fig. 2 ▸ a) to pPvPM (72%) than to pPM II (64%) and to pHAP (59%), showing that the zymogens pPM IV and pPvPM have greater structural similarity. Structural studies of the similarities and differences between the structure of pPM IV and the structures of its mature enzyme and of the other proplasmepsins will provide more information about the inactivation mechanism by the propeptide and insight for future drug design.
Figure 2.
Comparison of proplasmepsins: pPM IV, pPvPM, pPM II and pHAP. (a) Structure-based sequence alignment (performed with ESPript; Robert & Gouet, 2014 ▸) of the four proplasmepsins. The prosegment is underscored with a blue bar, the N-terminal fragment (residues 1–13) with a red bar and the flap loop with a yellow bar. (b) Superposition of the zymogen structures of PM IV (green), PvPM (orange), PM II (magenta) and HAP (lilac) in two orientations related by a rotation of 90°. The regions discussed in the text are shown in darker colours and labelled, and the catalytic Asp34/His34–Asp214 is shown as sticks. The Tyr122p–Asp4 loop and the flap loop are highlighted with a black circle and a black rectangle, respectively. (c, d) Close-up views showing the conformational differences among proplasmepsins in the loop comprised of residues Tyr122p–Asp4 and the flap loop, respectively. Salt bridges and hydrogen bonds are shown as dashed lines and the side chains of the residues involved in the interactions are shown as sticks. (c) The main chain of residues Ser1–Asp4 (pPM IV) and Asn3–Asp4 (pPvPM) are shown as sticks. (d) The angle between the flap loop of pPM IV and of pPM II is shown at the bottom.
2. Materials and methods
2.1. Expression and purification
The proenzyme of plasmepsin IV, with a prosegment of 47 residues, was overexpressed using the pET-3a vector (Novagen) in Escherichia coli BL21 (DE3) cells. The protein was isolated from inclusion bodies. Refolding and purification were performed as described by Beyer et al. (2004 ▸).
The purified pPM IV was concentrated to 14 mg ml−1 in 20 mM Tris–HCl pH 8.0 using a 10 kDa cutoff Amicon concentrator. Stocks of 50 µl protein solution were flash-frozen in liquid nitrogen and stored at −80°C.
2.2. Crystallization and data collection
pPM IV at 14 mg ml−1 in 20 mM Tris–HCl pH 8.0 was crystallized by vapour diffusion using MRC 96-well sitting-drop plates (Molecular Dimensions) by mixing 1 µl protein solution with 1 µl reservoir solution consisting of 100 mM sodium citrate pH 4.7, 25%(w/v) PEG 3350, 200 mM ammonium acetate (Table 1 ▸). The obtained crystals were cryoprotected in reservoir solution containing 30%(v/v) glycerol and flash-cooled in liquid nitrogen.
Table 1. Crystallization.
Method | Vapour diffusion |
Plate type | MRC 96-well sitting-drop plate |
Temperature (K) | 293 |
Protein concentration (mg ml−1) | 14 |
Buffer composition of protein solution | 20 mM Tris–HCl pH 8.0 |
Composition of reservoir solution | 100 mM sodium citrate pH 4.7, 25%(w/v) PEG 3350, 200 mM ammonium acetate |
Volume and ratio of drop | 2 µl, 1:1 |
Volume of reservoir (µl) | 100 |
Data from pPM IV crystals were collected on beamline I911-3 at the MAX-lab synchrotron, Lund, Sweden. Images were processed by iMosflm (Leslie et al., 2002 ▸; Powell et al., 2013 ▸) and scaled using SCALA (Evans, 2006 ▸) from the CCP4 suite (Winn et al., 2011 ▸).
2.3. Structure solution and refinement
The orientation and position of pPM IV were solved using the molecular-replacement program Phaser (McCoy et al., 2007 ▸) in the CCP4 suite (Winn et al., 2011 ▸), using pPM II (PDB entry 1pfz; Bernstein et al., 2003 ▸), which presents 67% sequence homology, as a model (Fig. 2 ▸ a). Rigid-body refinement followed by Cartesian simulated annealing was initially applied to the structure using PHENIX (Echols et al., 2014 ▸), which resulted in a high-quality electron-density map for the manual rebuilding of the pPM IV structure. The model was improved by iterative cycles of manual rebuilding with Coot (Emsley & Cowtan, 2004 ▸) in combination with σA-weighted 2F o − F c and F o − F c maps and automated refinement with PHENIX, applying a hybrid TLS–isotropic ADP model.
Statistics of data collection, final refinement and validation by MolProbity (Chen et al., 2010 ▸) are summarized in Tables 2 ▸ and 3 ▸. The superposition of models and the r.m.s. deviations were calculated using LSQKAB in the CCP4 suite (Winn et al., 2011 ▸). Buried surfaces and residues at the intermolecular contacts in the crystals were identified with the PISA server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html; Krissinel & Henrick, 2007 ▸), and the CONTACT program in the CCP4 suite (Winn et al., 2011 ▸) was used to study the interactions. The figures were generated with UCSF Chimera (Pettersen et al., 2004 ▸) and CCP4mg (McNicholas et al., 2011 ▸).
Table 2. Data collection and processing.
Values in parentheses are for the outer resolution shell.
Diffraction source | I911-3, MAX-lab |
Wavelength (Å) | 0.97 |
Temperature (K) | 100 |
Detector | MAR CCD |
Crystal-to-detector distance (mm) | 153.9 |
Rotation range per image (°) | 0.20 |
Total rotation range (°) | 130 |
Space group | P21 |
Unit-cell parameters (Å, °) | a = 82.91, b = 62.78, c = 94.03, α = 90, β = 113.50, γ = 90 |
Mosaicity (°) | 0.56 |
Resolution (Å) | 48.41–1.53 (1.55–1.53) |
R meas (%) | 7.9 (7.9) |
R p.i.m. (%) | 4.5 (5.0) |
Total No. of reflections | 342658 (13264) |
No. of unique reflections | 129149 (6237) |
Completeness (%) | 96.3 (95.1) |
〈I/σ(I)〉 | 7.5 (1.2) |
Multiplicity | 2.7 (2.1) |
Wilson B factor (Å2) | 18.2 |
CC1/2 | 0.995 (0.330) |
Table 3. Structure refinement.
Values in parentheses are for the outer resolution shell.
Resolution (Å) | 36.68–1.53 |
Completeness (%) | 96.3 (95.9) |
No. of reflections, working set | 122621 (5965) |
No. of reflections, test set | 6883 [5.33%] |
R work/R free | 0.179/0.209 |
No. of atoms | |
Protein | 5947 |
Water | 689 |
Ligand (glycerol) | 54 |
Average B factors (Å2) | |
Overall | 30.3 |
Protein | 28.8 |
Ligand | 62.8 |
Water | 40.5 |
R.m.s. deviations | |
Bond lengths (Å) | 0.007 |
Bond angles (°) | 1.070 |
Ramachandran plot | |
Most favoured (%) | 98.0 |
Outliers (%) | 0.0 |
MolProbity overall score | 1.36 |
MolProbity clashcore | 3.19 |
The coordinates and structure factors for pPM IV have been deposited in the Protein Data Bank as entry 5jod.
3. Results and discussion
The fragment of the PM IV zymogen that was crystallized consisted of the C-terminal prosegment truncated to 47 residues, denominated 78p–124p, followed by the sequence corresponding to the mature enzyme. This truncated proplasmepsin IV is inactive at neutral pH, and undergoes autoactivation at pH 4.4 when incubated at 37°C (unpublished data; Fig. 1 ▸ b; PM IV; PDB entry 1ls5; Asojo et al., 2003 ▸).
3.1. Overall structure and comparison to other proplasmepsins
pPM IV crystallized in space group P21 with two molecules in the crystallographic asymmetric unit. The monomers superpose very well for the trans-motif and C-terminal domain, with the major differences present in the N-terminal domain, with monomer B in a more closed conformation (data not shown). The r.m.s. deviation between monomers A and B is around 1.9 Å for the Met15–Val140 Cα atoms. Although the electron density for certain portions of the prosegment of both monomers (Ser115p–Lys120p; Supplementary Fig. S1), and Glu7–Asp10 of the mature fragment of monomer B, was poor, it was still possible to model the structure of all of these residues. The Glu7–Asp10 residues correspond to a short 310-helix (Fig. 1 ▸ a) and have been described previously in other proplasmepsin structures (Bernstein et al., 1999 ▸, 2003 ▸; Bhaumik et al., 2011 ▸). This short helix is found on the surface of the C-terminal domain (Fig. 1 ▸ a) and is part of the fragment 1–13 that undergoes conformational changes upon the activation of the proenzyme from a random coil and 310-helical conformation to a β-strand in concert with its relocation from the surface of the C-domain into the central β-sheet at the back of the active-site cleft (Fig. 1 ▸ b).
The overall fold of the truncated pPM IV is quite similar to the previously reported zymogens (Fig. 2 ▸ b) pPM II (Bernstein et al., 1999 ▸) and pHAP (Bhaumik et al., 2011 ▸) from P. falciparum and pPvPM from P. vivax (Bernstein et al., 2003 ▸). Fig. 2 ▸(a) shows the sequence homology of the proplasmepsins with known structures, and we can see that the major sequence differences among zymogens are localized in the prosegment region, although all of them conserve the secondary-structure motif of a β-strand for the fragment Thr80p–Asp87p, which is followed by two α-helices: α1, Pro90p–Asn100p, and α2, Leu102p–Lys114p (Fig. 2 ▸ b). The α1 helices of pPM II and pHAP superpose very well with each other, but not with the helices from pPM IV or pPvPM, which are shorter. The second α-helix of pPM IV superposes better with α2 from pPM II than with those from the other zymogens. It is evident that the prosegment structure of pPvPM, including both α-helices and the connecting loop, is rather different from the prosegments of the other zymogens. The loop connecting the two α-helices is very flexible, and is displaced by about 7 Å in pPvPM with respect to the other proplasmepsins, affecting the conformation of the loop Tyr273–Cys285, which assumes an in-conformation in pPMs but is in an out-conformation in pPvPM (Fig. 2 ▸ b). Although the C-terminal domain of the mature enzyme presents high sequence homology, the residues of the loop Tyr273–Cys285 are not so well conserved (Fig. 2 ▸ a).
The pro–mature junction, Gly124p–Ser1, is located in a tight loop delimited by Tyr122p and Asp4, the ‘Tyr-Asp’ loop (Fig. 2 ▸ c). These loops superpose well in the structures of pPM IV and pPM II, but they are displaced by 2.4 Å in relation to that of pPvPM, and in the pHAP structure this loop is disordered (Fig. 2 ▸ b). The fold of the loop is stabilized by hydrogen-bond interactions between the carboxylate of Asp4 and the phenolic hydroxyl of Tyr122p and, in the structure of pPvPM, also with the hydroxyl group of Ser1. Asp4 is also involved in a hydrogen-bond interaction with the main-chain amide group of Phe241 and a salt bridge to the amino group of Lys238 (Fig. 2 ▸ c).
3.2. Flap-loop conformation
For the study and comparison of the flap-loop conformation we used the unpublished structure of pPM II with PDB entry 5bwy, instead of that described in the literature (PDB entry 1pfz; Bernstein et al., 1999 ▸), as the flap-loop residues of the 5bwy structure have been modelled and some important interactions of these residues could be compared with the other pPMs.
The structures of pPM IV and pPvPM present a more closed conformation of the flap loop than the zymogens of PM II and HAP (Fig. 2 ▸ b). On superimposition of the structures, the flap loop of pPM IV and the flap loop of pPM II form an angle of approximately 25° (Figs. 2 ▸ b and 2 ▸ d). The different conformations of the flap loops translate into dissimilarities in their interactions (Fig. 2 ▸ d), as well as differences in the conformation of nearby areas (Fig. 2 ▸ b). The loop Trp128–Asp137 borders the flap on the prime (Sn′) side of the substrate-binding site. Although all its residues are conserved among the proplasmepsins studied (Fig. 2 ▸ a), it acquires a different conformation in each of the proplasmepsin structures (Fig. 2 ▸ b). In pPvPM and pHAP it folds towards the cleft, pointing Leu131 into the S2′ pocket, while in pPM IV and pPM II this loop points away from the cleft, leaving a deeper pocket (Fig. 2 ▸ b).
The segment from Ala108 to Pro113, which contacts the flap on the nonprime (Sn) side, and the following α-helix (residues Ile114–Glu119) has a different sequence in pPM IV compared with all other zymogens. The α-helices of zymogens pPM IV and pPvPM superpose well (Fig. 2 ▸ b), but they do not superpose either with the helix of pPM II or with that of pHAP.
In the structures of pPM IV and pPvPM that show the closed conformation of the flap loop, Tyr77 interacts with Trp41 (Fig. 2 ▸ d). However, in pPMII and pHAP the open conformation of the flap loop accommodates another rotamer of Trp41 that is not possible in the closed-flap conformation owing to clashes with Ile75 (Fig. 2 ▸ d). In the open conformation Trp41 establishes a hydrogen-bond interaction with Ser37, which interacts with the catalytic Asp34 in the proenzymes of PM IV and PvPM. In some structures of the mature PM II both conformations of Trp41 are present (Prade et al., 2005 ▸; Rasina et al., 2016 ▸). The presence of this pocket in pPM II and pHAP (Fig. 2 ▸ d) makes the binding of an inhibitor to them entropically more favourable than in the mature enzymes (Carcache et al., 2002 ▸). This cannot be considered for either pPM IV or pPvPM as they lack this hydrophobic pocket.
3.3. pPM IV prosegment interactions and plasmepsin activation
Proplasmepsins present high sequence and structural homology, with the major differences being localized in the prosegment (Fig. 2 ▸ a). Despite this, the prosegment is involved in numerous well conserved hydrogen bonds and hydrophobic interactions (Fig. 3 ▸). The side chains of Lys78p and His79p form salt-bridge interactions with the carboxylic group of Asp150 and their main-chain amide groups form hydrogen bonds to the carboxylic group of Glu174, as has been reported for the other proplasmepsins (Bernstein et al., 1999 ▸; Bhaumik et al., 2011 ▸). These two residues are followed by the first strand of the β-sheet (Thr80p–Asp87p), which is replaced by Asp4–Val11 of the mature enzyme upon activation (Fig. 1 ▸) and forms similar interactions (Fig. 3 ▸ a). These residues are involved in the formation of an antiparallel β-sheet with a string of hydrogen bonds to Ile170–His164 of the mature enzyme, which are highly conserved in the enzymes studied, with the exception of Val165, which differs in each of the enzymes (Fig. 2 ▸ a). The hydroxyl group of Thr80p, which is not conserved in the other proplasmepsins (Fig. 2 ▸ a), interacts with the carboxylic group of Asp95. As described for the other proplasmepsins (Bernstein et al., 1999 ▸, 2003 ▸; Bhaumik et al., 2011 ▸), the hydroxyl group of Thr81p forms a hydrogen bond to the hydroxyl group of Thr169, and the side chains of Ile82p, Phe84p and Ile86p fit into hydrophobic pockets lined by residues of the mature portion of pPM IV (Fig. 3 ▸ a). Lys85p and Asp87p are engaged in four antiparallel β-sheet hydrogen bonds to Leu14 and Phe16 as part of an N-domain β-sheet. Lys85p and Asp87p interact with residues of the other monomer of the crystallographic asymmetric unit. The amino group of Lys85p forms salt-bridge interactions with the carboxylate group of Asp279, and the carboxylate group of Asp87p, the last residue of the β-strand, forms a salt bridge with the amine group of Lys101. These two interactions have not been described in the other structures.
Figure 3.
pPM IV prosegment interactions. Interactions made by the β-strand and α1 and α2 of the prosegment (C atoms in grey) with the mature portion (C atoms in green) are shown, with salt bridges and hydrogen bonds shown as dashed lines. (a) β-Strand (80p–87p). (b) α1 (Pro90p–Asn100p). (c) α2 (Leu102p–Lys114p). (d) Interactions between the α2 of two symmetry-related molecules. The loops Lys238–Tyr245 and Pro276–Ala283 are shown in green.
Pro88p–Val14 wrap around the C-terminal domain (Fig. 1 ▸ a). An equivalent feature has been observed in the other proplasmepsins (Bernstein et al., 1999 ▸, 2003 ▸; Bhaumik et al., 2011 ▸) and has been called the ‘harness’. This ‘harness’ plays a crucial role in keeping the zymogen inactive at neutral pH, as it establishes hydrogen-bond interactions which help to separate the two domains, the N-domain and C-domain, of the proplasmepsins (Fig. 1 ▸). In the case of pPM IV these interactions are disrupted at a pH of around 4.0–4.4 (Li et al., 2004 ▸) and the enzyme is activated (Fig. 1 ▸). The self-activation of pPvPM and pPM II has also been described, but at a pH that is a little higher (Bernstein et al., 2003 ▸; Hill et al., 1994 ▸). The lower pH causes protonation of the aspartate residue of the Tyr122p–Asp4 loop (Fig. 2 ▸ d), resulting in disruption of the hydrogen bonds made by its side chain and subsequent opening of the loop (Bernstein et al., 1999 ▸). Other hydrogen-bonding interactions between the prosegment and the C-terminal domain of the mature polypeptide chain are also disrupted at low pH (Bernstein et al., 1999 ▸, 2003 ▸; Bhaumik et al., 2011 ▸). Compared with the zymogen, in the mature enzyme reorientation of the N-domain occurs in a more closed conformation (Fig. 1 ▸).
The α1 helix (Pro89p–Leu98p) does not present high sequence homology among the four proplasmepsins, with pPM IV showing the greatest difference (Fig. 2 ▸ a). Only Asp91p is present in all of them and forms hydrogen-bond interactions with the imidazole N atom of His164, which is conserved in pPvPM and pPM II but not in pHAP (Asn164). The hydrophobic residues of α1 (Val93p, Leu94p, Val97p and Leu98p) are involved in interactions with residues from the C-terminal domain of the mature PM IV polypeptide and loops (Fig. 3 ▸ b). The hydroxyl group of Ser96p interacts with the side-chain amide of Asn100p. These two residues are only present in pPM IV. The rest of the α1 residues are exposed towards the solvent.
In all structures, the α2 helix is positioned in a hydrophobic groove formed by two loops (Lys238–Tyr245 and Pro276–Ala283), maintaining a hydrogen bond to the mature portion from the hydroxyl group of Tyr105p (conserved in all of the proplasmepsins; Fig. 2 ▸ a) to the main-chain O atom of Pro240 (Fig. 3 ▸ c). The first loop, residues Lys238–Tyr245, presents high sequence homology among the different proplasmepsins (Fig. 2 ▸ a). However, in pHAP the substitution of Pro243 by a serine makes its loop structure very different from the other three structures (Fig. 2 ▸ b). Additionally, Leu244 in pPM IV and pHAP is mutated to a phenylalanine in pPM II and pPvPM. Major differences are present within the loop Lys238–Tyr245 (Fig. 3 ▸ c). In addition to showing greater sequence diversity (Fig. 2 ▸ a), this loop has an in-conformation in pPM II, pPM IV and pHAP, while in pPvPM it adopts an out-conformation (Fig. 2 ▸ b). pPM IV presents the largest sequence differences in the prosegment α2, which are translated to the interactions, so that pPM IV does not present some of the polar interactions that have been observed in pPM II (Bernstein & James, 1999 ▸).
Besides the interactions described above, α-helix 2 of the prosegment is also involved in intermolecular interactions with α2 from another crystallographic symmetry-related molecule (Fig 3 ▸ d). The buried surface area between monomers of pPM IV is 4210 Å2. This dimer is stable in solution, as observed by size-exclusion chromatography during purification (data not shown). The same dimerization has been described for the other plasmepsin zymogens (Bernstein & James, 1999 ▸; Bernstein et al., 2003 ▸; Bhaumik et al., 2011 ▸) and they present similar mostly hydrophobic interactions (Fig. 3 ▸ d).
4. Summary
In summary, the crystal structure of the PM IV zymogen revealed a conformation of the prosegment that is similar to those found in its counterparts pPvPM, pPMII and pHAP, suggesting a common mechanism of inactivation/activation. Some differences include the interactions of the nonconserved residues of the prosegments and mature enzyme, as well as the different conformations adapted by the proplasmepsin structure parts. Similarly to pPvPM, pPM IV shows a closed conformation of the flap loop and does not have the cavity in the substrate-binding site that is present in the other two proplasmepsins, pPM II and pHAP. This cavity, which has been described as a target for the design of inhibitors against pPM II and pHAP, is created by the open conformation of the flap loop featuring a rotamer of Trp41 which cannot be accommodated in the pPM IV and pPvPM structures owing to clashes with Ile75.
Supplementary Material
PDB reference: proplasmepsin IV, 5jod
Supporting Information: Supplementary Figure S1.. DOI: 10.1107/S2053230X16011663/wd5264sup1.pdf
Acknowledgments
This study was supported by the InnovaBalt project (EU-Grant-316149) and the FP7 program Biostruct-X proposal 7869. We thank the staff of the MAX-lab synchrotron for their support during data collection.
References
- Asojo, O. A., Gulnik, S. V., Afonina, E., Yu, B., Ellman, J. A., Haque, T. S. & Silva, A. M. (2003). J. Mol. Biol. 327, 173–181. [DOI] [PubMed]
- Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M. & Goldberg, D. E. (2002). Proc. Natl Acad. Sci. USA, 99, 990–995. [DOI] [PMC free article] [PubMed]
- Bernstein, N. K., Cherney, M. M., Loetscher, H., Ridley, R. G. & James, M. N. G. (1999). Nature Struct. Mol. Biol. 6, 32–37. [DOI] [PubMed]
- Bernstein, N. K., Cherney, M. M., Yowell, C. A., Dame, J. B. & James, M. N. G. (2003). J. Mol. Biol. 329, 505–524. [DOI] [PubMed]
- Bernstein, N. K. & James, M. N. G. (1999). Curr. Opin. Struct. Biol. 9, 684–689. [DOI] [PubMed]
- Beyer, B. B., Goldfarb, N. E. & Dunn, B. M. (2004). Curr. Protoc. Protein Sci., Unit 21.14. 10.1002/0471140864.ps2114s32. [DOI] [PubMed]
- Bhaumik, P., Xiao, H., Hidaka, K., Gustchina, A., Kiso, Y., Yada, R. Y. & Wlodawer, A. (2011). Biochemistry, 50, 8862–8879. [DOI] [PMC free article] [PubMed]
- Carcache, D. A., Hortner, S. R., Bertogg, A., Binkert, C., Bur, D., Marki, H. P., Dorn, A. & Diederich, F. (2002). Chembiochem, 3, 1137–1141. [DOI] [PubMed]
- Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. [DOI] [PMC free article] [PubMed]
- Coombs, G. H., Goldberg, D. E., Klemba, M., Berry, C., Kay, J. & Mottram, J. C. (2001). Trends Parasitol. 17, 532–537. [DOI] [PubMed]
- Dame, J. B., Yowell, C. A., Omara-Opyene, L., Carlton, J. M., Cooper, R. A. & Li, T. (2003). Mol. Biochem. Parasitol. 130, 1–12. [DOI] [PubMed]
- Echols, N., Moriarty, N. W., Klei, H. E., Afonine, P. V., Bunkóczi, G., Headd, J. J., McCoy, A. J., Oeffner, R. D., Read, R. J., Terwilliger, T. C. & Adams, P. D. (2014). Acta Cryst. D70, 144–154. [DOI] [PMC free article] [PubMed]
- Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. [DOI] [PubMed]
- Evans, P. (2006). Acta Cryst. D62, 72–82. [DOI] [PubMed]
- Francis, S. E., Gluzman, I. Y., Oksman, A., Knickerbocker, A., Mueller, R., Bryant, M. L., Sherman, D. R., Russell, D. G. & Goldberg, D. E. (1994). EMBO J. 13, 306–317. [DOI] [PMC free article] [PubMed]
- Hill, J., Tyas, L., Phylip, L. H., Kay, J., Dunn, B. M. & Berry, C. (1994). FEBS Lett. 352, 155–158. [DOI] [PubMed]
- Jaudzems, K., Tars, K., Maurops, G., Ivdra, N., Otikovs, M., Leitans, J., Kanepe-Lapsa, I., Domraceva, I., Mutule, I., Trapencieris, P., Blackman, M. J. & Jirgensons, A. (2014). ACS Med. Chem. Lett. 5, 373–377. [DOI] [PMC free article] [PubMed]
- Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. [DOI] [PubMed]
- Le Bonniec, S., Deregnaucourt, C., Redeker, V., Banerjee, R., Grellier, P., Goldberg, D. E. & Schrével, J. (1999). J. Biol. Chem. 274, 14218–14223. [DOI] [PubMed]
- Leslie, A. G. W., Powell, H. R., Winter, G., Svensson, O., Spruce, D., McSweeney, S., Love, D., Kinder, S., Duke, E. & Nave, C. (2002). Acta Cryst. D58, 1924–1928. [DOI] [PubMed]
- Li, T., Yowell, C. A., Beyer, B. B., Hung, S.-H., Westling, J., Lam, M. T., Dunn, B. M. & Dame, J. B. (2004). Mol. Biochem. Parasitol. 135, 101–109. [DOI] [PubMed]
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
- McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011). Acta Cryst. D67, 386–394. [DOI] [PMC free article] [PubMed]
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). J. Comput. Chem. 25, 1605–1612. [DOI] [PubMed]
- Powell, H. R., Johnson, O. & Leslie, A. G. W. (2013). Acta Cryst. D69, 1195–1203. [DOI] [PMC free article] [PubMed]
- Prade, L., Jones, A. F., Boss, C., Richard-Bildstein, S., Meyer, S., Binkert, C. & Bur, D. (2005). J. Biol. Chem. 280, 23837–23843. [DOI] [PubMed]
- Rasina, D., Otikovs, M., Leitans, J., Recacha, R., Borysov, O. V., Kanepe-Lapsa, I., Domraceva, I., Pantelejevs, T., Tars, K., Blackman, M. J., Jaudzems, K. & Jirgensons, A. (2016). J. Med. Chem. 59, 374–387. [DOI] [PubMed]
- Recacha, R., Leitans, J., Akopjana, I., Aprupe, L., Trapencieris, P., Jaudzems, K., Jirgensons, A. & Tars, K. (2015). Acta Cryst. F71, 1531–1539. [DOI] [PMC free article] [PubMed]
- Robert, X. & Gouet, P. (2014). Nucleic Acids Res. 42, W320–W324. [DOI] [PMC free article] [PubMed]
- Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
- World Health Organization (2013). World Malaria Report 2013. Geneva: World Health Organization. http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/.
- Wyatt, D. M. & Berry, C. (2002). FEBS Lett. 513, 159–162. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
PDB reference: proplasmepsin IV, 5jod
Supporting Information: Supplementary Figure S1.. DOI: 10.1107/S2053230X16011663/wd5264sup1.pdf